AGER-Dependent Macropinocytosis Drives Resistance to KRAS-G12D–Targeted Therapy in Advanced Pancreatic Cancer

The authors found that advanced glycosylation end product–specific receptor (AGER) contributed to MRTX1133 resistance in PDAC through modulation of macropinocytosis and glutathione synthesis using patient-derived xenografts and orthotopic and genetically engineered mouse models.